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OBJECTIVE: This study examines the prognostic significance of human papillomavirus (HPV) in patients with locally advanced
oropharyngeal squamous cell carcinoma (SCC) treated primarily with surgery or definitive radiotherapy.
METHODS: One hundred and ninety-eight patients with Stage 3/4 SCC were followed up for recurrence in any form or death from any
cause for between 1 and 235 months after diagnosis. HPV status was determined using HPV E6-targeted multiplex real-time PCR/
p16 immunohistochemistry. Determinants of recurrence and mortality hazards were modelled using Cox’s regression with censoring
at follow-up dates.
RESULTS: Forty-two per cent of cancers were HPV-positive (87% type 16). HPV predicted loco-regional control, event-free survival
and overall survival in multivariable analysis. Within the surgery with adjuvant radiotherapy (n¼110), definitive radiotherapy-alone
(n¼24) and definitive radiotherapy with chemotherapy (n¼47) groups, patients with HPV-positive cancers were one-third or less
as likely to have loco-regional recurrence, an event or to die of any cause as those with HPV-negative cancers after adjusting for age,
gender, tumour grade, AJCC stage and primary site. The 14 patients treated with surgery alone were considered too few for
multivariable analysis.
CONCLUSION: HPV status predicts better outcome in oropharyngeal cancer treated with surgery plus adjuvant radiotherapy as well as
with definitive radiation therapy±chemotherapy.
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It is now accepted that human papillomavirus (HPV) is an
aetiological agent of up to 60% of oropharyngeal squamous cell
carcinomas (SCCs) (Gillison et al, 2000; Vidal and Gillison, 2008) and
there have been recent reports that the incidence of HPV-induced
oropharyngeal cancer is increasing (Frisch et al, 2000; Hammarstedt
et al, 2006; Hong et al, 2010c). Our studies and others have shown
that the HPV-positive subset of cancers is biologically distinct (Andl
et al, 1998; Li et al, 2003a; Weinberger et al, 2006; Fakhry et al,2 0 0 8 ;
Vidal and Gillison, 2008; Lassen et al, 2009; Sedaghat et al,2 0 0 9 ;
Hong et al, 2010a,b). Most notable has been the association of HPV
with a favourable clinical outcome.
Radiation therapy has an important role in the management of
oropharyngeal cancers, either as definitive therapy or as an
adjuvant therapy after surgery. Altered fractionation and con-
current chemotherapy have been developed to maximise disease
control (Pignon et al, 2000; Bourhis et al, 2006). Recent studies
have provided evidence that the favourable prognosis associated
with HPV relates to a better response to radiation therapy used
either alone (Lassen et al, 2009; Sedaghat et al, 2009) or in
combination with chemotherapy (Kumar et al, 2007; Fakhry et al,
2008). There are, however, limited data on the relationship of HPV
status to the outcome of oropharyngeal cancers treated with
surgery with or without adjuvant radiation therapy (Licitra et al,
2006; Fischer et al, 2008, 2010).
There is increasing use of HPV status to guide treatment
of oropharyngeal SCC (Shoushtari et al, 2010). This
study examines the effect of HPV on outcomes after surgery
with adjuvant radiation therapy or with definitive radiation
therapy (with or without chemotherapy) in a large series of
locally advanced oropharyngeal SCCs from the same geographic
region.
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Study population
Investigations were carried out on 202 consecutive patients with
AJCC Stage 3 and 4 oropharyngeal SCC treated with curative
intent at hospitals in Sydney, Australia, between 1987 and 2006.
One hundred and forty-six cases were from Royal Prince Alfred
Hospital. Human papillomavirus status for two patients could
not be determined (a 71-year-old man with a Stage 3 tonsillar
SCC treated with definitive radiation therapy and a 46-year-old
man with a Stage 4 oropharyngeal SCC treated with definitive
radiation therapy and concurrent chemotherapy), and two patients
were missing adequate follow-up data (a 46-year-old man with a
Stage 4 tonsillar SCC and a 68-year-old man with Stage 4 tonsillar
SCC), leaving 198 patients. The study was approved by the
ethics committees of Sydney South West Area Health Service
(Protocols X05-0308, CH62/6/2006-041, 2006/055). Most of the
demographic and clinicopathological data were retrieved from the
database of the Sydney Head and Neck Cancer Institute at Royal
Prince Alfred Hospital, which spans the study period. Department
of Radiation Oncology and Anatomical Pathology databases
and hospital records were used to verify and input missing data
as required.
Patients were followed up for the occurrence of an event, defined
as recurrence in any form or death from any cause, for between
1 and 235 (median 26) months after diagnosis. Patients who did
not experience an event before the end of follow-up were known at
that date to be alive and free of recurrence.
Laboratory studies
HPV status of cancers Evidence that HPV is transcriptionally
active or localised to the nuclei of tumour cells is needed to
establish causality in head and neck cancer (Vidal and Gillison,
2008). Overexpression of p16 resulting from downregulation of
retinoblastoma protein by HPV E7 has been used as a surrogate
marker of HPV E7 expression in several studies (Klussmann et al,
2003; Licitra et al, 2006). In our study, an HPV-positive cancer was
defined as one testing positive for both HPV DNA and p16 (Smeets
et al, 2007). The presence and type of HPV DNA were determined
on two to six 4–5mm sections of formalin-fixed paraffin-
embedded cancer, using an HPV E6-based multiplex real-time
PCR assay (MT-PCR) modified from the method of Stanley and
Szewczuk (2005). This assay simultaneously detects and identifies
21 HPV types (16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68, 70,
73, 82, 53, 6, 11 and 26). The HPV 16 assay (Supplementary Figure 1)
has a sensitivity of 400 viral genome copies per ml at the 95%
confidence level (CI) and compares well with our nested PCR
method, which was validated against previously published PCR
methods (Brestovac et al, 2005). DNA was extracted using the RNA
QIAmp RNA viral mini kit (Qiagen, Hilden, Germany). The first
step involved incorporation of all primer pairs into two PCR mixes
and amplification for 20 cycles in a conventional thermocycler.
Products from each of these mixes were then passed into triplex
TaqMan real-time PCR assays with probes having FAM, VIC or
Cy5 labels and cycling performed for 40 cycles in a real-time
thermocycler (RotorGene 6000, Corbett Research, Mortlake, NSW,
Australia). A Corbett CAS 1200 robot was used to inoculate
samples and to make the transfers from the initial PCR into the
TaqMan PCR mixes. A measured amount of equine herpesvirus
was introduced into the extraction lysis buffer and used to monitor
the efficiency of DNA extraction and removal of PCR inhibitors.
Stringent precautions were used to minimise the possibility of
cross-contamination. Section cutting was carried out in an
institution remote from that used for the PCR analyses; microtome
blades were cleaned with xylene between blocks, and changed
frequently. PCR procedures were carried out in a laboratory
equipped with separate rooms for preparing reagents, extracting
samples, handling PCR products and for thermocycling. Water
blanks were included after every fifth sample. The presence
of cancer cells in sections used for HPV testing was confirmed
by a pathologist (CSL) in an H&E-stained section cut after those
for HPV analysis. All discrepant HPV DNA/p16 results were
confirmed by retesting for both HPV DNA and p16. No attempt
was made to microdissect cancer from surrounding tissue.
Expression of p16 was carried out by semiquantitative
immunohistochemistry. Antigen retrieval was carried out using
Target Retrieval Solution pH9 (Dako Corporation, Carpinteria, CA,
USA) in a microwave oven for 10min on high setting. After
cooling, slides were placed in an autostainer (Dako). Endogenous
peroxidase was blocked using 0.3% hydrogen peroxide in
Tris-buffered saline (TBS); sections were incubated with primary
antibody (Clone JC2 Neomarkers, Fremont, CA, USA) (one out of
200) for 30min, washed in TBS, treated with the EnVision Flex
Dual Link horseradish peroxidase/DAB visualisation system
(Dako) and then counterstained with haematoxylin. Staining was
evaluated by three observers, including at least one pathologist
(CSL). Typically, strong diffuse p16 staining was seen in the
nucleus and cytoplasm of cancer cells with the proportion
essentially all or none (Supplementary Figures 2a and 2b). Weak
focal staining was recorded as negative. All researchers were
blinded to clinical and other laboratory data until results were
finalised. The grade for all cancers was reviewed by two study
pathologists (CSL, JRK). Any variation from a previous report or
between observers was resolved over a double-headed microscope.
Statistical analyses
Associations between HPV status and clinicopathological charac-
teristics were assessed using a two-sample t-test for the continuous
variable age and chi-squared tests for categorical variables.
One-way analysis of variance and chi-squared tests were used
to compare patient characteristics in four treatment groups:
surgery alone; surgery with adjuvant radiation therapy; definitive
radiation therapy alone; and definitive radiation therapy with
chemotherapy.
Survival analyses were conducted for the outcomes of
loco-regional recurrence, event-free survival and overall survival,
with time to each outcome calculated from the date of diagnosis.
An event was defined as recurrence in any form or death from
any cause, with only the first event taken into account. Patients
without events were censored at the date of last follow-up.
Univariate associations between HPV status and time to
loco-regional recurrence, an event or death from any cause, were
summarised for all patients and separately for each treatment
group using Cox’s proportional hazards models. Unadjusted
survival curves were obtained using Kaplan–Meier estimates.
Overall multivariable survival models were constructed with
inclusion of HPV status and other known or potential correlates of
outcome: age, gender, tumour grade, AJCC stage, primary site
and treatment modality. Multivariable survival models were
constructed separately for the three radiation therapy treatment
groups, adjusting for HPV status, age, gender, tumour grade, AJCC
stage and primary site where possible. Multivariable analyses were
not carried out for the surgery-alone group because of the small
numbers (14).
We assessed whether the effect of HPV differed by treatment
type by using interaction terms between HPV status and treatment
(categorised as surgery with adjuvant radiation therapy, definitive
radiation therapy with chemotherapy and definitive radiation
therapy alone), and adjusting only for age, tumour grade, tumour
stage and site to avoid potential overfitting problems owing to
small numbers. Adjusted survival curves by HPV status and
treatment were obtained for the three treatment groups using Cox
regression models, again adjusting only for age, tumour grade,
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for Windows (SAS Institute, Cary, NC, USA) and Stata Statistical
Software (Stata Corporation, College Station, TX, USA).
RESULTS
HPV status and type distribution
Forty-two per cent (83 out of 198) of the cancers were HPV-
positive. Human papillomavirus type 16 accounted for 87%
(72 out of 83) of the HPV-positive cases. Human papillomavirus
types 35 and 18 were the most common other HPV types. Five
cancers positive for HPV type 16 also contained a second HPV
type (two 35, one each of 33, 39 and 56). Twenty-one (11%) cancers
tested HPV DNA positive/p16 negative and three (2%) cancers
were HPV DNA negative/p16 positive (Supplementary Table 1).
The 21 HPV DNA-positive/p16-negative samples were included
in the HPV-negative group, as the molecular and phenotypic
characteristics of this group resemble those of HPV-negative/
p16-negative cancers (our unpublished data, Smeets et al, 2007;
Weinberger et al, 2009). The three patients with HPV-negative/
p16-positive cancers were excluded from further analyses because
it was not known whether they were induced by an HPV type
undetectable by the assay or were HPV negative (p16 upregulated
through an HPV-unrelated pathway). They were too few to analyse
separately. Thus, the total number of cancers in the final analysis
was 195.
The patients’ characteristics are summarised in Table 1.
Compared with patients with HPV-negative cancers, patients with
HPV-positive cancers were younger (mean age 54.4 vs 62.6 years,
Po0.0001), more likely to have primary disease in the tonsil
(P¼0.003) and had higher grade cancers (P¼0.002). Patients with
HPV-positive cancers were also more likely to have Stage 4 than
Stage 3 cancers (P¼0.03), and this was driven by more advanced
nodal disease (P¼0.02).
Treatment
The choice of treatment modality was based primarily on clinician
and institution preference. Of the 195 patients analysed, 14 were
treated with radical surgery alone (five declined adjuvant radiation
therapy, one died of other than head and neck cancer before
adjuvant radiation therapy and the remaining eight were not
referred for adjuvant radiation therapy for unknown reasons). One
hundred and ten patients were treated with surgery with adjuvant
radiation therapy (five with concurrent chemotherapy and five
with induction chemotherapy) (Table 1). Fourteen of the
17 patients with T3N0 tumours treated with surgery and adjuvant
radiotherapy had elective neck dissections. Seventy-one patients
were treated with definitive radiation therapy. Of these, 47 had
chemoradiotherapy (35 concurrent, 12 induction) and 24 had
radiation alone. Within the surgery with adjuvant radiotherapy
group, separate analysis of the 10 patients who received
chemotherapy was not carried out, and within the definitive
radiotherapy group, patients receiving concurrent radiotherapy
were grouped with those having induction chemotherapy because
of small numbers.
The 35 patients who received concurrent chemotherapy and
definitive radiation therapy (mainly 5-fluorouracil or 3-weekly
cisplatin) were treated between 1990 and 2006; all but three of
these patients were treated after 1996. These 35 patients were
equally divided between the HPV-positive and -negative groups.
Over the study period, there was a change in definitive radiation
dose scheduling from 60Gy in 30 fractions over 6 weeks in the
early 1990s to 70Gy in 35 fractions over 7 weeks from 1999. The
dose of adjuvant radiation therapy also increased over the study
period from 50Gy in 25 fractions to 60Gy in 30 fractions in more
recent years. All patients were treated with multiple photon fields
using standard fractionation. Patients receiving surgery alone were
older than other patients and patients receiving definitive radio-
therapy with chemotherapy were more likely to have tumours
located in the base of tongue (Table 2).
Outcome analyses
Effect of HPV status One patient was missing loco-regional
recurrence status, yielding 194 patients for analysis. Loco-regional
recurrence occurred in 54 (28%) of 194 patients: in four of the
14 (29%) patients treated with surgery alone, 24 of the 109 (22%)
patients treated with surgery and adjuvant radiation therapy, 10 of
the 25 (40%) patients treated with definitive radiotherapy alone
and 16 of the 47 (34%) patients treated with definitive radiation
therapy with chemotherapy. Recurrence occurred at the primary
site in 30 patients and in the regional nodal area (with disease
controlled at the primary site) in 24 patients. Sixteen patients
developed distant metastasis as the first site of recurrence, none of
whom had simultaneous loco-regional recurrence.
Table 1 Demographic and clinical characteristics of the study population
All
patients
(n¼195)
HPV
positive
(n¼83)
HPV
negative
(n¼112)
HPV-positive vs
HPV-negative
P-value
a
Mean age at
diagnosis
(range)
59.1
(range 34–84)
54.4
(range 34–84)
62.6
(range 44–84)
o0.0001
Gender
Males 159 (82%) 69 (83%) 90 (80%) 0.6
Females 36 (18%) 14 (17%) 22 (20%)
Location
Tonsil 124 (64%) 61 (73%) 63 (56%) 0.003
Base of tongue 36 (18%) 16 (19%) 20 (18%)
Other subsites 35 (18%) 6 (7%) 29 (26%)
T classification
b
T1 21 (11%) 13 (16%) 8 (7%) 0.03
T2 60 (31%) 31 (37%) 29 (26%)
T3 72 (37%) 23 (28%) 49 (44%)
T4 41 (21%) 16 (19%) 25 (23%)
N classification
b
N0 45 (23%) 12 (14%) 33 (30%) 0.02
N1 56 (29%) 21 (25%) 35 (32%)
N2 74 (38%) 39 (47%) 35 (32%)
N3 19 (10%) 11 (13%) 8 (7%)
Stage
3 78 (40%) 26 (31%) 52 (46%) 0.03
4 117 (60%) 57 (69%) 60 (54%)
Grade
1, 2 118 (61%) 40 (48%) 78 (70%) 0.002
3 77 (39%) 43 (52%) 34 (30%)
Treatment
Surgery alone
c 14 (7%) 4 (5%) 10 (9%) 0.7
Surgery and
adjuvant RT
d
110 (56%) 47 (57%) 63 (56%)
Definitive RT
alone
24 (12%) 10 (12%) 14 (13%)
Definitive RT
and CT
e
47 (24%) 22 (27%) 25 (22%)
Abbreviations: HPV¼human papillomavirus; RT¼radiation therapy; CT¼chemo-
therapy.
aTest for heterogeneity.
bOne missing observation.
cIncludes one patient
who also received induction CT.
dIncludes 10 patients who also received CT
(five induction and five concurrent).
eInduction CT (n¼12) and concurrent
CT (n¼35).
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HPV-positive cancers were less likely to recur loco-regionally than
were HPV-negative cancers (Table 3). This association remained
after adjustment for age, gender, grade, stage, primary site within
the oropharynx and treatment group (hazard ratio (HR)¼0.27;
95% CI: 0.13–0.52; Table 3).
There was little evidence that the effect of HPV on loco-regional
recurrence differed by treatment group (Figure 1A); P¼0.7 for
interaction between HPV status and treatment group in the
adjusted analysis. After adjustment for age, tumour grade and
tumour stage, the risk of loco-regional recurrence associated with
HPV-positive cancers relative to HPV-negative cancers was about
one-third (HR¼0.30; 95% CI: 0.10–0.82) in the surgery with
adjuvant radiation therapy group, one-eighth (HR¼0.12; 95%
CI: 0.01–0.61) in the definitive radiation therapy-alone group and
one-quarter (HR¼0.25; 95% CI: 0.06–0.79) in the definitive
radiation therapy with chemotherapy group (Table 3).
There were 99 events involving nine of the 14 (64%) patients
treated with surgery alone, 48 of the 110 patients (44%) treated
with surgery and adjuvant radiation therapy, 16 of the 24 (67%)
patients treated with definitive radiotherapy alone and 26 of the 47
(55%) patients treated with definitive radiation therapy and
chemotherapy. Univariate analysis of data from all patients
showed that patients with HPV-positive cancers were less likely
to suffer an event than those with HPV-negative cancers (Table 3).
This association remained after adjustment for age, gender, grade,
stage, primary site within the oropharynx and treatment type
(HR¼0.23; 95% CI: 0.14–0.39).
There was little evidence that the effect of HPV on event-free
survival differed by treatment group (Figure 1B); P¼0.4 for
interaction between HPV status and treatment group in the
adjusted analysis. After adjustment for age, tumour grade and
stage, the risk of an event associated with HPV-positive cancers
relative to HPV-negative cancers was about one fifth (HR¼0.19;
95% CI: 0.08–0.40) in the surgery with adjuvant radiation therapy
group, about one-seventh (HR¼0.14; 95% CI: 0.02–0.54) in the
definitive radiation therapy-alone group and about one-third
(HR¼0.36; 95% CI: 0.14–0.85) in the definitive radiation therapy
with chemotherapy group (Table 3).
There were 82 deaths from any cause involving seven of the
14 patients (50%) treated with surgery alone, 38 of the 110 patients
(35%) receiving surgery with adjuvant radiation therapy, 13 of the
24 patients (54%) receiving definitive radiotherapy alone and 24 of
the 47 patients (51%) receiving definitive radiation therapy with
chemotherapy. Univariate analysis of data from all patients showed
that patients with HPV-positive cancers were less likely to die
of any cause than those with HPV-negative cancers (Table 3). This
association remained after adjustment for age, gender, grade,
stage, primary site within the oropharynx and treatment type
(HR¼0.24, 95% CI: 0.13–0.42).
There was little evidence that the effect of HPV on overall
survival differed by treatment group (Figure 1C); P¼0.3 for
interaction between HPV status and treatment group in the
adjusted analysis. After adjustment for age, tumour grade and
stage, the risk of death from any cause associated with
HPV-positive cancers relative to HPV-negative cancers was almost
one-tenth (HR¼0.11; 95% CI: 0.04–0.28) in the surgery with
adjuvant radiation therapy group, almost one-tenth (HR¼0.11;
95% CI: 0.01–0.52) in the definitive radiation therapy-alone group
and about one-third (HR¼0.37; 95% CI: 0.13–0.90) in the
definitive radiation therapy with chemotherapy group (Table 3).
Effects of clinical variables On the basis of multivariable analyses
of all patients adjusting for HPV status, type of treatment was the
only clinical characteristic that showed evidence of an association
with loco-regional recurrence (P¼0.06), with the surgery and
adjuvant radiotherapy group having the lowest risk of loco-
regional recurrence and the surgery-only group having the highest
risk.
Multivariable predictors of event-free survival were identified as
stage (P¼0.0001), site of cancer (P¼0.04) and type of treatment
(P¼0.0003) after adjusting for HPV status. Poorer outcomes were
seen in Stage 4 patients, patients with cancer in sites other than
tonsil and patients receiving surgery only.
After adjusting for HPV status, clinical characteristics that
showed evidence of associations with overall survival were
identified as stage (Po0.0001), site of cancer (P¼0.001) and type
of treatment (P¼0.05). Again, poorest outcomes were seen in
Table 2 Characteristics of patients by treatment group
Surgery alone
(n¼14)
Surgery with adjuvant
RT (n¼110)
Definitive RT
alone (n¼24)
Definitive RT with
CT (n¼47) P-value
a
Mean age at diagnosis (range) 67.1 (44–84) 58.2 (34–84) 60.7 (38–84) 58.2 (38–83) 0.03
Gender
Males 10 (71%) 85 (77%) 22 (92%) 42 (89%) 0.1
Females 4 (29%) 25 (23%) 2 (8%) 5 (11%)
Location
Tonsil 9 (65%) 79 (72%) 16 (67%) 20 (43%) 0.02
Base of tongue 2 (14%) 16 (15%) 2 (8%) 16 (34%)
Other subsites 3 (21%) 15 (14%) 6 (25%) 11 (23%)
Stage
3 8 (57%) 39 (35%) 9 (38%) 22 (47%) 0.3
4 6 (43%) 71 (65%) 15 (63%) 25 (53%)
Grade
1, 2 10 (71%) 62 (56%) 15 (63%) 31 (66%) 0.5
3 4 (29%) 48 (44%) 9 (38%) 16 (34%)
HPV status
Negative 10 (71%) 63 (57%) 14 (58%) 25 (53%) 0.7
Positive 4 (29%) 47 (43%) 10 (42%) 22 (47%)
Abbreviations: CT¼chemotherapy; HPV¼human papillomavirus; RT¼radiation therapy.
aTest for heterogeneity.
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patients receiving surgery only.
When stratified by HPV status, outcome-adjusted survival
against each end point was consistently highest for surgery with
adjuvant radiotherapy, intermediate for definitive radiotherapy
with chemotherapy and lowest for definitive radiotherapy alone
(Figure 1A–C). (Patients treated with surgery alone were too few
to include in these comparisons.) These differences in outcome by
treatment type should be interpreted with caution because they are
not randomised comparisons and may be affected by confounding
by indications for particular treatment types. For each outcome,
there was little evidence that the effect of treatment type was
modified by stage or by site of cancer (P for interaction 40.3 in
each case).
DISCUSSION
Recent studies have suggested that the favourable outcome
associated with HPV in oropharyngeal cancer is owing to an
increased sensitivity of virus-related cancers to radiation therapy
or chemoradiotherapy (Fakhry et al, 2008; Kumar et al, 2008;
Lassen et al, 2009; Sedaghat et al, 2009). Data from patients treated
primarily with surgery (with or without adjuvant radiotherapy)
are limited, but there have been recent reports of a survival
advantage for those with HPV-positive cancers (Licitra et al, 2006;
Fischer et al, 2010). Our findings show that HPV status is a strong
predictor of loco-regional recurrence and survival in patients
treated either by surgery with adjuvant radiotherapy or by an
organ-preserving approach using definitive radiotherapy with or
without chemotherapy. Mounting evidence that the effect of HPV
on outcome in oropharyngeal cancer is independent of treatment
modality is not inconsistent with theories that HPV-positive
cancers are more radiosensitive than HPV-negative cancers, but
rather suggests that other factors including immune surveillance
to virus-specific tumour antigens and a lack of field cancerisation
(Mellin et al, 2000; Lindel et al, 2001) may have an important
contributing role.
As most recent studies have focused on HPV and outcome
following definitive radiotherapy or chemoradiotherapy, the
interest of this study centres on patients with surgery as primary
treatment. Our results suggest that outcomes in patients with
locally advanced HPV-positive cancers treated with surgery and
adjuvant radiotherapy were as good as, and possibly better than,
those treated with definitive radiotherapy with or without
chemotherapy. This also appeared to be the case for HPV-negative
cancers, and the effect of HPV status on outcome did not appear to
differ materially between these treatment groups. In their study of
patients with all stages of disease, Licitra et al (2006) reported an
effect of HPV on outcome in patients treated with surgery alone as
well as those receiving surgery with adjuvant radiotherapy. In our
study, overall outcomes were poorer in patients treated with
Table 3 Associations between HPV status and risk of recurrence, event and/or death
Treatment group
All
(n¼195)
Surgery alone
(n¼14)
Surgery with
adjuvant radiotherapy
(n¼110)
Definitive
radiotherapy
alone (n¼24)
Definitive radiotherapy
and chemotherapy
(n¼47)
HR
(95% CI) P-value
HR
(95% CI) P-value
HR
(95% CI) P-value
HR
(95% CI) P-value
HR
(95% CI) P-value
Loco-regional recurrence
Univariate
HPV
Negative 1.0 1.0 1.0 1.0 1.0
Positive 0.34 (0.17, 0.61) 0.0002 0.71 (0.04, 5.57) 0.8 0.38 (0.14, 0.91) 0.03 0.18 (0.03, 0.75) 0.02 0.36 (0.10, 1.03) 0.06
Adjusted
HPV
Negative 1.0 1.0 1.0 1.0
Positive 0.27 (0.13, 0.52)
a o0.0001 Not estimated
b 0.30 (0.10, 0.82)
c 0.02 0.12 (0.01, 0.61)
d 0.009 0.25 (0.06, 0.79)
c 0.02
Event-free survival
Univariate
HPV
Negative 1.0 1.0 1.0 1.0 1.0
Positive 0.31 (0.19, 0.49) o0.0001 0.50 (0.07, 2.10) 0.4 0.28 (0.13, 0.53) o0.0001 0.19 (0.04, 0.60) 0.004 0.46 (0.19, 1.03) 0.06
Adjusted
HPV
Negative 1.0 1.0 1.0 1.0
Positive 0.23 (0.14, 0.39)
a o0.0001 Not estimated
b 0.19 (0.08, 0.40)
c o0.0001 0.14 (0.02, 0.54)
d 0.003 0.36 (0.14, 0.85)
c 0.02
Overall survival
Univariate
HPV
Negative 1.0 1.0 1.0 1.0 1.0
Positive 0.29 (0.17, 0.48) o0.0001 0.98 (0.14, 4.57) 1.0 0.18 (0.07, 0.40) o0.0001 0.24 (0.05, 0.82) 0.02 0.43 (0.17, 0.99) 0.05
Adjusted
HPV
Negative 1.0 1.0 1.0 1.0
Positive 0.24 (0.13, 0.42)
a o0.0001 Not estimated
b 0.11 (0.04, 0.28)
c o0.0001 0.11 (0.01, 0.52)
d 0.004 0.37 (0.13, 0.90)
c 0.03
Abbreviations: HPV¼human papillomavirus; HR¼hazard ratio; CI¼confidence interval; RT¼radiation therapy; CT¼chemotherapy.
aAdjusted for age, gender, tumour grade,
tumour stage, primary site and treatment.
bMultivariable analyses not carried out owing to small numbers.
cAdjusted for age, gender, tumour grade, tumour stage and primary site.
dAdjusted for age, tumour grade and tumour stage; gender and primary site not adjusted owing to categories with low numbers of events.
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Figure 1 Probability of (A) remaining free from loco-regional recurrence, (B) survival free from an event and (C) overall survival by HPV status and type
of radiation therapy, adjusted for age, tumour grade, stage and site.
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ssurgery alone than in other treatment groups and there was only
weak evidence for a better outcome for HPV-positive cancers
treated with surgery alone on univariate analysis. However, we
only included patients with locally advanced disease who, in our
centre, have long been routinely referred for adjuvant radiotherapy
(six of the 14 patients did not have adjuvant radiation therapy as
recommended). The numbers receiving surgery only were too few
to adequately evaluate outcome by HPV status. It was, however,
worth noting that this group of patients tended to be older and to
have HPV-negative cancer.
The seemingly lower HRs for outcome of HPV-positive cancer
relative to HPV-negative cancer in the definitive radiotherapy-only
group than in the definitive radiotherapy with chemotherapy
group were unexpected. However, the wide CIs about the HRs and
the high P-values for interaction make any inference from this
difference very uncertain. Moreover, we cannot exclude selection
bias relating to performance status, co-morbidities, smoking and
alcohol exposure that might affect the HRs (Hafkamp et al, 2008;
Ang et al, 2010; Maxwell et al, 2010).
The heterogeneity of disease within the head and neck region is
well recognised. Although oropharyngeal SCCs are regarded as a
relatively homogeneous group, studies with the statistical power to
examine site within the oropharynx have found that patients with
base of tongue SCCs have the worst prognosis (Zhen et al, 2004;
Sundaram et al, 2005). Our overall findings indicate that site
within the oropharynx is an independent risk factor for survival
with tonsillar cancers having the best outcome. This finding
suggests that stratification of future trials of oropharyngeal cancer
by subsite may be worthwhile.
The proportion of oropharyngeal cancers attributable to HPV
has varied from 19% to more than 60% across different studies
(Gillison et al, 2000; Vidal and Gillison, 2008). Our overall HPV
positivity rate of 46% is lower than that reported in some recent
studies, but this is explained by the 20-year period of the study.
By 2005–2006, rates in our centre had risen to 66% (Hong et al,
2010c). This increase is consistent with trends in other western
countries (Frisch et al, 2000; Hammarstedt et al, 2006; Chaturvedi
et al, 2008). Variation in HPV-positivity rates across different
studies is also attributable to differences in the specificity and
sensitivity of the HPV detection assays. However, there do seem to
be geographic or ethnic differences (Li et al, 2003b, 2007), which
highlights the need for standardised procedures for determining
HPV status (Braakhuis et al, 2009). The proportion of our cancers
testing HPV DNA positive/p16 negative, indicating that the virus is
not causal, is lower than that in some studies (van Houten et al,
2001; Wiest et al, 2002; Weinberger et al, 2006), despite the high
sensitivity of our HPV DNA assay.
Testing for HPV status of oropharyngeal SCCs is increasing in
clinical practice, but there is no level 1 or 2 evidence to guide
treatment based on HPV status. We conclude that patients
with HPV-positive locally advanced oropharyngeal SCC have a
more favourable prognosis than HPV-negative cancers, regardless
of whether they are treated with radical surgery plus adjuvant
radiation therapy or by an organ-preserving approach using
definitive radiation therapy with or without chemotherapy.
The possibility that type of treatment, as well as HPV status,
may influence outcome warrants investigation in randomised
controlled trials.
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